Clinical trials: Anti-Glomerular Basement Membrane Disease
Vascular Access Complication, Apheresis Related Complication
Vascular Access Complications for Therapeutic Apheresis in Nephrology
The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology.
- Trial name
- VACTANE (NCT05894317)
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Kidney Failure, Acute
Comparison of ANCA and Anti-GBM Auto-antibodies Removal Kinetics Between Plasma Exchanges and Immunoadsorption in Patients With ANCA-associated Vasculitis or Anti-GBM Disease
Anti-neutrophil cytoplasmic antibodies (ANCA), directed against myeloperoxidase (MPO) and against proteinase 3 (PR3), have a pathogenic role during ANCA (AAV) vasculitis.
- Trial name
- CINEVAS (NCT03635385)
- Testing
- Apheresis technics
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Anti-Glomerular Basement Membrane Disease
Anti-Glomerular Basement Membrane Disease
This study aims to clarify the prognosis of the rare but severe condition anti-glomerular basement membrane disease (anti-GBM disease also known as Goodpastures disease).
- Trial name
- PRAGMATIC (NCT07018024)
- Where
- Sweden
- Volunteers
- 300 people
- Sponsor
- Region Skane
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease
A Study With Imlifidase in Anti-GBM Disease
An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone.
- Conditions
- Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
- Trial name
- GOOD-IDES-02 (NCT05679401)
- Testing
- Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC)
- Where
- 48 sites in United States, Austria and 11 more
- Volunteers
- 50 people
- Sponsor
- Hansa Biopharma AB
Autoimmune Diseases
Complement C5 mAb in the Treatment of Anti-GBM Disease
Anti-GBM disease is the most severe form of glomerulonephritis. Despite of the standard treatment including plasmapheresis and immunosuppressant, 70% of the patients still go into end-stage kidney disease.
- Trial name
- NCT06513338
- Testing
- Eculizumab
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Peking University First Hospital
Humoral Rejection, Guillain-Barre Syndrome
Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation
Plasma exchange procedures remove procoagulant and anticoagulant factors. Every procedure increases the risk of bleeding and repeated procedures increase the risk of bleeding mostly because lower fibrinogen levels.
- Conditions
- Humoral Rejection, Guillain-Barre Syndrome, Miller Fisher Syndrome, CIDP
- Trial name
- NCT03801135
- Testing
- Fibrinogen concentrate, Fresh Frozen Plasma
- Where
- Slovenia
- Volunteers
- 20 people
- Sponsor
- University Medical Centre Ljubljana
SLE, LN
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
An Exploratory, Single-Arm, Open-Label, Dose-Escalation Study of the Safety, Tolerability, PK, PD, and Efficacy of Anti-CD19/BCMA Universal CAR-T Therapy RD06-05 in Autoimmune Diseases (including SLE/LN, AAV/AAGN, Anti-GBM, MN…
- Conditions
- SLE, LN, ANCA Associated Vasculitis, ANCA-Associated Glomerulonephritis
- Trial name
- NCT07203404
- Testing
- RD06-05 CART Cell Injection
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Lupus Nephritis
Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)?
Introduction and background : Glomerulonephritis and auto-immune diseases are often associated. Lupus nephritis (LN) is one of the major clinical manifestations of systemic lupus erythematosus (SLE) which have a severe impact on…
- Trial name
- GOODLUPUS (NCT03664908)
- Testing
- Detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method).
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Anti-Glomerular Basement Membrane Disease
A Clinical Trial With KJ103 in Anti-GBM Disease
An open-label, single-arm Phase II study to evaluate the preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of KJ103 in patients with anti-GBM disease.
- Trial name
- NCT06607016
- Testing
- KJ103 for Injection, Cyclophosphamide, Glucocorticoids
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Bao Pharmaceuticals Co., Ltd.
Anti-Glomerular Basement Membrane Antibody Disease
Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease
This study will evaluate the safety and tolerability of IdeS in patients with severe anti-glomerular basement membrane (anti-GBM) disease receiving standard of care consisting of pulse-methylprednisolone, oral prednisolone and…
- Trial name
- GOOD-IDES-01 (NCT03157037)
- Testing
- Imlifidase
- Where
- 10 sites in Austria, Czechia and 3 more
- Volunteers
- 15 people
- Sponsor
- Mårten Segelmark